Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PLX

Protalix BioTherapeutics Inc

Dec 12 • 04:00PM ET

1.80

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Peers: SRPT BMRN ALNY FOLD ARWR BLUE QURE EDIT ABEO DTIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	7.57%	Shs Outstand	73.63M	Perf Week	10.43%
Market Cap	132.54M	Forward P/E	2.86	EPS next Y	0.63	Insider Trans	0.00%	Shs Float	68.06M	Perf Month	36.36%
Income	-9.61M	PEG	-	EPS next Q	0.08	Inst Own	5.21%	Short Float	4.72%	Perf Quarter	71.43%
Sales	45.67M	P/S	2.90	EPS this Y	-77.78%	Inst Trans	-31.52%	Short Ratio	11.25	Perf Half Y	55.17%
Book/sh	0.44	P/B	4.09	EPS next Y	3050.00%	ROA	-12.88%	Short Interest	3.22M	Perf Year	13.92%
Cash/sh	0.37	P/C	4.84	EPS next 5Y	25.00%	ROE	-27.18%	52W Range	0.82 - 1.90	Perf YTD	1.12%
Dividend Est.	-	P/FCF	18.49	EPS past 5Y	-	ROI	-26.24%	52W High	-5.26%	Beta	0.74
Dividend TTM	-	Quick Ratio	1.27	Sales past 5Y	19.48%	Gross Margin	35.86%	52W Low	119.14%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	1.98	EPS Y/Y TTM	-197.63%	Oper. Margin	-19.50%	RSI (14)	70.74	Volatility	3.33% 6.52%
Employees	208	Debt/Eq	0.18	Sales Y/Y TTM	-28.22%	Profit Margin	-21.03%	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	177.78%	Payout	0.00%	Rel Volume	1.88	Prev Close	1.80
Sales Surprise	10.46%	EPS Surprise	-50.00%	Sales Q/Q	73.60%	Earnings	Nov 14 BMO	Avg Volume	285.75K	Price	1.80
SMA20	7.82%	SMA50	34.25%	SMA200	49.91%	Trades		Volume	538,210	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy	$3 → $11
Apr-17-17	Reiterated	Rodman & Renshaw	Buy	$4 → $5
Apr-04-16	Initiated	Rodman & Renshaw	Buy	$3.50
Apr-23-15	Upgrade	Jefferies	Hold → Buy	$2 → $2.60
Nov-12-14	Reiterated	R. F. Lafferty	Buy	$8 → $5
Jan-24-14	Initiated	R. F. Lafferty	Buy	$8
May-02-12	Reiterated	Oppenheimer	Outperform	$9 → $11
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold	$8 → $8
Apr-30-12	Downgrade	Auriga	Buy → Hold	$8 → $8
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy	$10
Nov-09-10	Reiterated	Oppenheimer	Outperform	$10 → $12
Oct-14-10	Reiterated	UBS	Buy	$9 → $10.75
Dec-02-09	Reiterated	Hapoalim	Outperform	$10 → $12
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform	$10
Dec-01-08	Reiterated	Oppenheimer	Outperform	$6 → $4
Mar-11-08	Initiated	UBS	Buy	$6
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform	$7

Show Previous Ratings

Dec-10-24 10:35AM	EMA validates Chiesi and Protalixs dose variation for Fabry disease (Pharmaceutical Technology)
Dec-09-24 06:30AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa (PR Newswire)
Nov-15-24 02:10AM	Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
Nov-14-24 07:03AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance) +13.71%
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results (PR Newswire)
06:50AM	Loading…
Nov-07-24 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 (PR Newswire)
Oct-25-24 07:18AM	Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 (PR Newswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
08:35AM	Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 (GlobeNewswire)
Sep-04-24 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.61%
Sep-03-24 06:50AM	Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes (PR Newswire) +13.32%
Aug-30-24 08:38AM	Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-14-24 06:57AM	Protalix: Q2 Earnings Snapshot (Associated Press Finance) -10.58%
06:50AM	Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results (PR Newswire)
06:50AM	Loading…
Aug-07-24 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 (PR Newswire)
Jun-13-24 06:50AM	Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout (PR Newswire)
May-29-24 08:38AM	Protalix BioTherapeutics to Present at the 2024 BIO International Convention (PR Newswire)
May-13-24 03:05AM	Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-11-24 10:27AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 06:56AM	Protalix: Q1 Earnings Snapshot (Associated Press Finance) -12.00%
06:50AM	Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results (PR Newswire)
May-03-24 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 (PR Newswire)
Mar-15-24 01:17PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 08:11AM	Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023 (GuruFocus.com) -9.87%
06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results (PR Newswire)
Mar-07-24 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 (PR Newswire)
Feb-23-24 06:50AM	Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference (PR Newswire)
Dec-26-23 06:50AM	Protalix BioTherapeutics Issues 2024 Letter to Stockholders (PR Newswire)
Nov-30-23 04:00AM	Levicept Appoints Eliot Forster as CEO (GlobeNewswire) +5.59%
09:04AM	Loading…
Nov-07-23 09:04AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:04AM	Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results (GuruFocus.com) -18.38%
06:58AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results (PR Newswire)
Oct-30-23 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 (PR Newswire)
Oct-09-23 06:50AM	Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel (PR Newswire) -6.71%
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-06-23 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-08-23 09:14AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:51AM	PLX: Second Quarter Results (Zacks)
Aug-07-23 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results (PR Newswire) +14.46%
Aug-01-23 06:50AM	Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-31-23 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 (PR Newswire)
Jun-08-23 06:50AM	Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease (PR Newswire)
May-30-23 11:00AM	PLX: Back of the Envelope (Zacks Small Cap Research)
06:50AM	Protalix BioTherapeutics Issues Letter to Stockholders (PR Newswire)
May-23-23 06:50AM	Protalix BioTherapeutics set to join Russell 3000® Index (PR Newswire) +7.55%
May-18-23 06:50AM	Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases (PR Newswire) -9.32%
May-11-23 07:59AM	PLX: FDA Approval of Elfabrio (Zacks Small Cap Research) -13.27%
May-10-23 04:16PM	Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics (Benzinga)
06:00AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease (PR Newswire)
May-08-23 02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com) -7.03%
May-05-23 07:26AM	PLX: One Down, One to Go (Zacks Small Cap Research)
06:46AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease (PR Newswire)
May-04-23 06:50AM	Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results (PR Newswire) +6.67%
Apr-27-23 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023 (PR Newswire)
Mar-21-23 06:50AM	Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout (PR Newswire)
Mar-13-23 06:50AM	Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank (PR Newswire)
Feb-28-23 08:52PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript (Insider Monkey)
04:32AM	PLX: May is a Big Month (Zacks Small Cap Research)
Feb-27-23 06:30AM	Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results (PR Newswire)
Feb-24-23 09:15AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease (PR Newswire) +7.06%
Feb-21-23 06:55AM	Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium 2023 (PR Newswire)
06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023 (PR Newswire)
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research) +6.99%
Jan-03-23 06:50AM	Protalix BioTherapeutics Issues 2023 Letter to Stockholders (PR Newswire)
Dec-21-22 04:30PM	Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange (PR Newswire) -7.81%
Dec-05-22 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease (PR Newswire) +5.31%
Dec-04-22 09:00AM	Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102 (PR Newswire)
Nov-30-22 02:59PM	Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment (News Direct)
Nov-15-22 04:46AM	PLX: BLA Submitted: 1H:23 Responses (Zacks Small Cap Research)
Nov-14-22 06:50AM	Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results (PR Newswire)
06:30AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease (PR Newswire)
Nov-07-22 06:50AM	Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022 (PR Newswire)
Sep-21-22 08:00AM	Under The Hood Of Options Chain Implications Understanding How Options Data Can Help Inform Investment Decisions (News Direct)
Sep-12-22 12:40PM	Protalix BioTherapeutics to Present in Person at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Sep-06-22 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-16-22 05:55AM	PLX: Eyes on Upcoming BLA Resubmission (Zacks Small Cap Research)
Aug-15-22 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results (PR Newswire)
Aug-08-22 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022 (PR Newswire)
Jun-30-22 04:30PM	Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors (PR Newswire)
Jun-14-22 09:23AM	10 Popular Penny Stocks on Robinhood (Insider Monkey)
May-26-22 04:30PM	Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease (PR Newswire)
May-17-22 06:13AM	PLX: First Quarter Financial and Operational Review (Zacks Small Cap Research)
May-16-22 06:50AM	Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results (PR Newswire)
May-09-22 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022 (PR Newswire) -7.49%
Apr-07-22 10:05AM	10 Penny Stocks to Buy in April (Insider Monkey) -9.62%
Apr-05-22 07:40AM	PLX: Topline Results from BALANCE (Zacks Small Cap Research)
Apr-04-22 06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease (PR Newswire) +41.90%
Apr-01-22 06:22AM	PLX: Fourth Quarter and Fiscal Year 2021 Financial and Operational Review (Zacks Small Cap Research)
Mar-31-22 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results (PR Newswire)
Mar-24-22 06:50AM	Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022 (PR Newswire)
Mar-18-22 09:54AM	Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease (Benzinga) +12.89%
06:50AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease (PR Newswire)
Mar-07-22 07:00AM	Revenue Diversification Strategy Continues to Deliver (PR Newswire)
Feb-28-22 04:45AM	PLX: MAA Submitted (Zacks Small Cap Research)
Feb-24-22 07:27AM	Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease (PR Newswire)
Feb-03-22 06:50AM	Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium 2022 (PR Newswire)
Dec-22-21 06:50AM	Protalix BioTherapeutics Issues 2021 Letter to Stockholders (PR Newswire)
Nov-15-21 10:18AM	PLX: Third Quarter Update (Zacks Small Cap Research)

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLX

Protalix BioTherapeutics Inc

Upgrade your FINVIZ experience